Open AccessPromising areas of research on the pharmacogenetics of dabigatran etexilate
Author(s) -
А. В. Савинова,
Н. А. Шнайдер,
М. М. Петрова,
Р. Ф. Насырова
Publication year - 2020
Publication title -
farmakogenetika i farmakogenomika
Language(s) - English
Resource type - Journals
eISSN - 2686-8849
pISSN - 2588-0527
DOI - 10.37489/2588-0527-2020-1-35-41
Subject(s) - dabigatran , prodrug , pharmacology , medicine , pharmacogenetics , pharmacokinetics , gene , chemistry , biochemistry , warfarin , atrial fibrillation , genotype
Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. It is considered that CES1 enzyme and P-glycoprotein (CES1 and ABCB1 genes accordingly) play important role in pharmacokinetics of dabigatran etexilate. UDP-glucuronosyltransferase enzymes UGT2B15, UGT1A9, UGT2B7 (UGT2B15, UGT1A9, UGT2B7 genes accordingly) take part in the metabolism of active dabigatran. Presence of these gene’s single-nucleotide variants (SNV) can affect effectiveness and safety of dabigatran etexilate usage. The goal of this review is analysis of promising areas of associated researches of SNV of genes CES1 and ABCB1 and search for new candidate genes that reveal effectiveness and safety of dabigatran etexilate usage.